• Home
  • Paras Biopharmaceuticals Finland Oy

Paras Biopharmaceuticals Finland Oy

About Paras Biopharmaceuticals Finland Oy

Company activities & offerings are categorized in 3 major areas:

1. Contract development & microbial biologics manufacturing (CDMO):The company offers end-to-end services for production of microbial recombinant proteins. 

2. Development of Recombinant expression systems and process technologies for biologics and biosimilars: Recombinant IL1-RA / Anakinra (Kineret® Biosimilar) and Recombinant Romiplostim (Nplate® Biosimilar).

3. Recombinant Bioprocess Enzymes:  offering Enterokinase & TEV Protease.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • FI
  • 2018
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Contact info
Show contact info Hide contact info

Products from Paras Biopharmaceuticals Finland Oy (5)

  • Anakinra Biosimilar Candidate

    Product Anakinra Biosimilar Candidate

    Paras Biopharmaceuticals has been intensively working on a Anakinra / IL1-RA biosimilar known as Kineret™) and has progressively achieved success. The company plans to mature good value within its Anakrina / IL1-RA asset and would like to highlight the following points / highlights to gauge your level of ...
  • RapidEK® (Recombinant Enterokinase)

    Product RapidEK® (Recombinant Enterokinase)

    Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes. This includes Recombinant Enterokinase (RapidEK®). As a type 2 transmembrane serine protease, enterokinase is ideally suited for the biotechnological and biochemical removal of fusion proteins and cleavage of tags after purifica...
  • RapidTEV® Protease (Recombinant TEV Protease)

    Product RapidTEV® Protease (Recombinant TEV Protease)

    Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes including Recombinant Tev Protease (RapidTEV®). RapidTEV® Protease is a site-specific protease that has been engineered for enhanced activity and greater stability. Due to its high specificity it is frequently used for the clea...
  • Rasburicase Biosimilar candidate

    Product Rasburicase Biosimilar candidate

    Paras Biopharmaceuticals has been intensively working on a Romiplostim biosimilar known as Elitek™ / Fasturtec™) and has progressively achieved success. The company plans to mature good value within its Rasburicase asset and would like to highlight the following points / highlights to gauge your level of ...
  • Romiplostim Biosimilar Candidate

    Product Romiplostim Biosimilar Candidate

    Due to the complex nature of the product, Paras Biopharmaceuticals has been intensively working on this complex drug (Nplate™) for over 6 years and has progressively achieved success. The company plans to mature good value within its Romiplostim asset (Biosimilar) and would like to highlight the following...